Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate

BACKGROUND: Recombinant human interleukin-2 (rhIL-2, aldesleukin) is Food and Drug Administration approved for the treatment of metastatic melanoma and renal cell carcinoma and has achieved durable response in a subset of patients. However, its utility as an immunotherapeutic drug is limited by unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Merchant, Rosemina, Galligan, Carole, Munegowda, Manjunatha Ankathatti, Pearce, L Bruce, Lloyd, Peter, Smith, Paul, Merchant, Fahar, To, Minh D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772458/
https://www.ncbi.nlm.nih.gov/pubmed/35058325
http://dx.doi.org/10.1136/jitc-2021-003155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772458/
https://www.ncbi.nlm.nih.gov/pubmed/35058325
http://dx.doi.org/10.1136/jitc-2021-003155

Ejemplares similares